Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

AstraZeneca

Novartis

Regeneron Pharmaceuticals

The oncology treatment market has been experiencing significant growth lately. Companies like Regeneron Pharmaceuticals (REGN), Merck & Co. (MRK), Novartis (NVS) and AstraZeneca (AZN) have made meaningful contributions in cancer treatment.

Oncology Market's Huge Potential Puts These Stocks in Focus

Merck & Co Inc (NYSE:MRK) and research partner Eisai said they are halting a late-stage trial that used a combination of drugs to treat a type of head and neck cancer after it didn't result in an overall survival benefit for patients. In a statement, the companies said the Phase 3 LEAP 010 trial evaluated Merck's anti-PD-1 therapy Keytruda together with Eisai's Lenvima, an orally available multiple receptor tyrosine kinase inhibitor (TKI) for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).

Merck and Eisai cull late-stage study for head and neck cancer therapy

Merck & Co. Inc. MRK, -1.66% and Eisai Co. Ltd. 4523, -1.23% ESAIY, -1.95% said Friday a late-stage trial of a treatment for head and neck cancer failed to meet its main goals and the companies have decided to shut it down.

Merck and Eisai say late-stage trial of treatment for head and neck cancer did not meet goals

Merck & Co and partner Eisai said on Friday they will shut down a late-stage study testing an experimental combination therapy for a type of head and neck cancer after an interim analysis showed it failed to prolong lives of patients.

Merck, Eisai discontinue late-stage study for cancer therapy

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of the company's Phase 3 clinical program, CORALreef, for MK-0616, an investigational, oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, being evaluated for the treatment of adults with hypercholesterolemia. This is the first Phase 3 clinical program for an oral PCSK9 inhibitor. The first participants are now enrolling in two registrational P.

Merck Initiates Phase 3 Clinical Program for Oral PCSK9 Inhibitor Candidate MK-0616

RAHWAY, N.J. & NUTLEY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck and Eisai Provide Update on Phase 3 LEAP-010 Trial Evaluating KEYTRUDA + LENVIMA in Patients With Certain Types of Recurrent or Metastatic HNSCC.

Merck and Eisai Provide Update on Phase 3 LEAP-010 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Patients With Certain Types of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--LYNPARZA Plus Abiraterone and Prednisone or Prednisolone Approved in Japan for the Treatment of BRCA-Mutated mCRPC.

LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone Approved in Japan for the Treatment of BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer

With continued label expansion into new indications, particularly earlier-line launches, Merck's (MRK) Keytruda is expected to remain a key top-line driver.

Will Keytruda Remain Merck's (MRK) Key Top-Line Driver?

Roche Holding AG

Gilead Sciences

Cancer drug stocks were boosted on Wednesday after Roche accidentally published positive interim results from its lung cancer treatment study. The Swiss drugmaker said that it had been made aware of the inadvertent disclosure of the second interim analysis from its Phase 3 study evaluating its investigational anti-TIGIT (T cell immunoreceptor with immunoglobulin and ITIM domains) immunotherapy tiragolumab in combination with the established immune-oncology drug Tecentriq for people with lung cancer.

Cancer drug stocks soar after Roche accidentally releases positive interim lung cancer trial results

Based on interim data from a late-stage study, Merck's (MRK) Welireg achieves statistically significant improvements in one of the study's dual endpoints of progression-free survival.

Merck's (MRK) Welireg Meets Renal Cell Carcinoma Study Goals

On August 1, Merck released its financial report for the second quarter of 2023, which showed excellent results. Merck's revenue for the second quarter of 2023 was $15.04 billion, up 3.8% from the previous quarter and up 3.1% from the second quarter of 2022. The active R&D policy, which is being implemented under the leadership of Robert Davis, is one of the main factors contributing to the increase in Merck's revenue.

Is Merck's Long-Term Investment Brilliance Unshaken By COVID-19 Drug Sales Slump?

Chevron

JPMorgan Chase & Co

Macy's

Republic Services

Southern Company

The artificial intelligence rally this year, led by the so-called Magnificent 7, has been awesome if you owned those stocks.

Dividend Lovers Bet Big on 6 ‘Strong Buy' Goldman Sachs Conviction List Picks for Rest of 2023

Pfizer

There are sectors in the economy that go through an extended period of trending sideways to lower. A good example is the pharmaceutical sector.

The 3 Most Undervalued Pharma Stocks to Buy Now: August 2023

Merck's revenues have increased by 31% over the last decade, driven by sales volume, price increases, and M&A activity. The company has a strong track record of increasing dividends annually for the past 11 years, with room for further growth as EPS increases. The current valuation of Merck is attractive, with a P/E ratio of less than 13 when considering forecasted EPS for 2024.

Despite The One-Time Charge, Merck Is Still A Buy

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces WELIREG Phase 3 LITESPARK-005 Trial Met Primary Endpoint of PFS in Certain Previously Treated Patients With Advanced RCC.

Merck Announces WELIREG® (belzutifan) Phase 3 LITESPARK-005 Trial Met Primary Endpoint of Progression-Free Survival in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma

Merck (NYSE: MRK ) has consistently delivered impressive financial results, built a robust product portfolio, and demonstrated an unwavering commitment to research and development. Given this, I think Merck could be a good stock to consider here.

Buy Merck (MRK) Stock Now to Ride a Wave Higher in Healthcare

Bristol-Myers

First Trust Nasdaq Pharmaceuticals ETF 

iShares U.S. Pharmaceuticals ETF

Johnson & Johnson

Eli Lilly

Invesco Dynamic Pharmaceuticals ETF

VanEck Vectors Pharmaceutical ETF

SPDR S&P Pharmaceuticals ETF

Second-quarter earnings beat ratio of 86.6% and revenue beat ratio of 84.9% for the healthcare sector are impressive.

Pharma ETFs in Focus Post Q2 Earnings

Bunge Global SA

Valvoline

It's a common assumption that the best ESG (environmental, social, governance) stocks to buy may be profitable for your inner wellbeing but not necessarily for your portfolio. After all, doing the right thing in our personal lives usually comes at a cost; either a direct one or a cost associated with a lack of recognition of upright behavior or action.

The 3 Best ESG Stocks to Buy in August

Amgen

It's still unclear which drugs Medicare will select, but several companies have revealed in court filings that four of their medications are targets.

These 10 medications are likely targets for Medicare price negotiations this fall

The drug giant pours massive amounts into R&D -- nearly a quarter of its revenue. Seven of Merck's medications boast more than $1 billion in annual sales.

My Oh My, Merck Stock Is a No-Brainer Income Stock to Buy

Merck's crown jewel, Keytruda, is still the star of the show. There are other pieces to the company's business.

Is Merck Stock a Buy Now?

Thermo Fisher Scientific

UnitedHealth Group

Health is undoubtedly the most important thing for all of us. It's vital to be able to continue with our day-to-day and to be able to carry out everything we want to throughout our lives.

The 3 Best Healthcare Stocks to Buy in August

AbbVie

Accenture Plc

Automatic Data Processing

Applied Materials

ASML Hld

Best Buy

Blackrock Inc

Cisco Systems

Expeditors International of Washington

Fastenal

Ferguson Enterprises Inc

Garmin

Home Depot

Infosys

KLA-Tencor

Lockheed Martin

Lowe's

Lam Research

Mastercard

Monolithic Power Systems

Paychex

Rollins

Schwab US Dividend Equity ETF

Snap-on

Skyworks Solutions

Taiwan Semiconductor Manufacturing

Texas Instruments

The 4-factor dividend growth portfolio is a strategy that leverages the stock selection process of Schwab U.S. Dividend Equity ETF™, with a few minor twists. The portfolio gained 2.44% in July, underperforming the S&P 500 by 0.77%. Year-to-date, the portfolio is up 14.72%. Since inception, the portfolio is generating 2.75% of alpha over the S&P 500.

4 Factor Dividend Growth Portfolio - Performance Since Launch

News for Merck Stock (MRK)